Merck invests in Canadian research after cutbacks; Theravance gets mixed result from FDA panel;

 @FierceBiotech: From Study: Genomics, outsourcing fuel double-digit growth in bioinformatics. Report | Follow @FierceBiotech

 @JohnCFierce: BioCryst ends a very bad, disastrous, no good of any kind of month by terminating merger pact. News | Follow @JohnCFierce

 @RyanMFierce: Sounds like adult blood could best skin cells as source for stem cells. We'll see. BBC report. More | Follow @RyanMFierce

> After cutbacks in Canada, Merck ($MRK) pledged $12.5 million in funding for translational studies and basic research at three research centers in Montreal. Article  

> 20/20 Gene Systems, a Rockville, MD-based biotech outfit, has urged its home state to award it $2 million to fund cancer research. Maryland's Cigarette Restitution Fund is the source from which the company is requesting funds. Report

> The FDA accepted Eisai's new drug application (NDA) for a delayed-release version of its AcipHex for treating kids with gastroesophageal reflux disease. Release

> An FDA panel was mixed about use of Theravance's ($THRX) antibiotic Vibativ for treating hospital-acquired pneumonia. Article

Pharma News

@FiercePharma: Ranbaxy stops making generic Lipitor as news of 2nd recall surfaces. Story | Follow @FiercePharma

> Teva will cut $2 billion in costs to get ahead, CEO Levin says. Article

> Presidio, BioCryst call off $101 million merger. Item

> Theravance wins partial victory for Vibativ. News

Medical Device News

 @FierceMedDev: eBay co-founder invests heavily in India's medtech industry. Item | Follow @FierceMedDev

@MarkHFierce: Indictments filed in a long-standing med device insider trading case. An ex-Angels ball player is involved. More | Follow @MarkHFierce

 @DamianFierce: With St. Jude's $1B stock repurchase, the company says the future will be stable. Do investors agree? Story | Follow @DamianFierce

> Stryker commits to $30M R&D expansion in Ireland. Report

> Boston Scientific aims for FDA approval with absorbable stent trial. News

> FDA says it's already speeding up device approvals. Article

And Finally... Space researchers found water on Mercury. The suspected source: Interstellar ice balls. Article

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.